Caplyta is Intra-Cellular Therapies oral lumateperone treatment for schizophrenia and bipolar depression.
Competing Products
Intra-Cellular Therapies
NY-based Intra-Cellular Therapies develops drugs for neuropsychiatric, neurologic, and CNS disorders.
Founded
2002Intra-Cellular Therapies, founded in New York, focuses on developing innovative drugs for the treatment of neuropsychiatric and neurologic diseases, as well as other disorders of the central nervous system (CNS). The company's core mission is to improve the lives of patients suffering from these conditions through scientific research and clinical development. Their flagship product, Caplyta (lumateperone), is approved for the treatment of schizophrenia and bipolar depression, targeting a significant market need for effective CNS disorder treatments.
Notable affiliated individuals include Dr. Sharon Mates, who has played a crucial role in the company's development. Key investors have included prominent venture capital firms that specialize in life sciences. Intra-Cellular Therapies' achievements include FDA approval for Caplyta, which has made a substantial impact on the treatment landscape for schizophrenia and bipolar depression. The company's ongoing research and development efforts continue to contribute to advancements in neuropsychiatric and neurologic therapeutics.
Intra-Cellular Therapies - M & A Snapshot
Intra-Cellular Therapies - Quick Facts
Who are Intra-Cellular Therapies' competitors?
Companies similar to Intra-Cellular Therapies include Bristol Myers Squibb, Supernus Pharmaceuticals, Acorda Therapeutics and Psy Therapeutics.
When was Intra-Cellular Therapies founded?
Intra-Cellular Therapies was founded in 2002.
Where is Intra-Cellular Therapies' headquarters located?
Intra-Cellular Therapies' headquarters is located in New York City, NY, US.